We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Rapid Test for Chlamydia Antigen Antibodies Optimized

By LabMedica International staff writers
Posted on 07 May 2019
Print article
Image: A Pgp3 LFA-dipstick test. After approximately 4 hours, the LFA-dipstick was inserted into the well for 15 to 20 minutes, and then LFA buffer was added (A). LFAs were read when the membrane was completely cleared of background staining (B) (Photo courtesy of the CDC).
Image: A Pgp3 LFA-dipstick test. After approximately 4 hours, the LFA-dipstick was inserted into the well for 15 to 20 minutes, and then LFA buffer was added (A). LFAs were read when the membrane was completely cleared of background staining (B) (Photo courtesy of the CDC).
Trachoma, resulting from repeated infection with the bacterium Chlamydia trachomatis (Ct), is the leading infectious cause of blindness. Trachoma is targeted for elimination as a public health problem by 2020.

Serological surveillance for trachoma could allow monitoring of transmission levels in areas that have achieved elimination targets. Platforms that allow testing in basic laboratories or testing of easy-to-manage samples such as dried blood spots would contribute to the feasibility of serologic testing.

An international team of scientists led by the Centers for Disease Control and Prevention (Atlanta, GA, USA) collected blood from 506 1 to 12-year-olds in two villages in Kongwa district, Tanzania. The blood was tested for antibodies against the antigen Pgp3. Whole blood, plasma, and dried blood spots (DBS) were tested in laboratory and field settings using a cassette-enclosed Pgp3 lateral flow assay (LFA-cassette) and a pared-back “dipstick” assay (LFA-dipstick). DBS were also tested with a bead-based multiplex assay (MBA). Pooled ocular swab testing for Ct infection was performed using the GeneXpert CT/NG cartridge.

In the field evaluation of LFA-cassette using whole blood, the percent positive was 42.5% and the sensitivity was 84.2%. In the field evaluation of LFA-cassette using plasma, the percent positive was 48.4% and the sensitivity was 94.7%. The percent agreement between LFA-cassette and LFA-dipstick was 93.8%. The percent agreement between the MBA and each LFA format and sample type ranged from 92.3% to 94.7%. The percent positive by MBA was 45.5%, and the sensitivity was 94.7%. Interrater agreement between an expert rater and three different raters in field and laboratory settings was uniformly good.

The authors concluded that despite the minor differences in individual tests run, there were no significant differences in the percentage of positive samples as determined by MBA or any LFA tests. The data suggest that the LFA, in any number of iterations, and MBA could potentially be used interchangeably in a population-level, programmatic setting based on the program needs. The study was published in the April 2019 issue of the journal Diagnostic Microbiology and Infectious Disease.

Related Links:
Centers for Disease Control and Prevention

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Piezoelectric Micropump
Disc Pump
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.